ReviewAdvances in experimental medicine and biology2026
Methods for the Investigation of Protein-Ligands Interactions.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomolecular interactions involving proteins, nucleic acids, and small molecules constitute the molecular foundation of cellular regulation, signaling, and therapeutic intervention. Advances in mass spectrometry-based proteomics have enabled the systematic characterization of these interactions at unprecedented depth, sensitivity, and structural resolution. This chapter provides a comprehensive overview of state-of-the-art proteomics methodologies developed to investigate protein-protein, protein-nucleic acid, and protein-drug interactions, with particular emphasis on experimental design, sample preparation, and data quality control. Targeted and untargeted strategies are discussed, including affinity purification-mass spectrometry, proximity-dependent labeling, cross-linking mass spectrometry, blue native electrophoresis, and size-exclusion chromatography-mass spectrometry for protein-protein interactions; affinity capture, EMSA-MS, chromatin immunoprecipitation-mass spectrometry, CRISPR-based locus-specific enrichment, and CLIP-based approaches for protein-nucleic acid complexes; and chemoproteomics, thermal proteome profiling, and label-free structural proteomics for protein-drug interaction analysis. The chapter further highlights recent technological innovations, computational tools, and integrative multi-omics strategies that enhance interaction mapping across biological scales. By critically evaluating the strengths, limitations, and appropriate applications of each methodology, this work aims to provide practical guidance for researchers seeking to design robust interactomics experiments and to interpret complex molecular networks in both basic and translational research contexts.
Indexed as
Identifiers
42401778What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.